Showing results (11-20 of 28) with videos related to
Sort By:
Pageof 3
Headache|April 1, 2021
A link between gastrointestinal disorders and migraine: Insights into the gut-brain connectionSheena K Aurora, Stephen B Shrewsbury, Sutapa Ray, et al.Headache|January 20, 2019
STOP 101: A Phase 1, Randomized, Open-Label, Comparative Bioavailability Study of INP104, Dihydroergotamine Mesylate (DHE) Administered Intranasally by a I123 Precision Olfactory Delivery (POD® ) Device, in Healthy Adult SubjectsStephen B Shrewsbury, Maria Jeleva, Kelsey H Satterly, et al.Pain Management|June 20, 2023
INP104: a drug evaluation of a nonoral product for the acute treatment of migraineAmaal J Starling, Theresa Mallick-Searle, Stephen B Shrewsbury, et al.Headache|June 24, 2009
A randomized, double blind, placebo-controlled study of MAP0004 in adult patients with migraineSheena K Aurora, Todd D Rozen, Shashidhar H Kori, et al.Current Medical Research and Opinion|June 7, 2008
Randomized, double-blind, placebo-controlled study of the safety, tolerability and pharmacokinetics of MAP0004 (orally-inhaled DHE) in adult asthmaticsStephen B Shrewsbury, Shashidhar H Kori, S David Miller, et al.Headache|January 9, 2008
Safety and pharmacokinetics of dihydroergotamine mesylate administered via a Novel (Tempo) inhalerStephen B Shrewsbury, Robert O Cook, Glyn Taylor, et al.The Journal of Urology|March 13, 2016
A Phase II Study of the Efficacy and Safety of the Novel Oral SHIP1 Activator AQX-1125 in Subjects with Moderate to Severe Interstitial Cystitis/Bladder Pain SyndromeJ Curtis Nickel, Blair Egerdie, Edward Davis, et al.The Journal of Headache and Pain|November 22, 2022
Variability in recurrence rates with acute treatments for migraine: why recurrence is not an appropriate outcome measureStewart J Tepper, Jessica Ailani, Sutapa Ray, et al.Journal of Aerosol Medicine and Pulmonary Drug Delivery|September 15, 2022
Delivery of Dihydroergotamine Mesylate to the Upper Nasal Space for the Acute Treatment of Migraine: Technology in ActionWade Cooper, Sutapa Ray, Sheena K Aurora, et al.Frontiers in Neurology|December 11, 2023
New characterization of dihydroergotamine receptor pharmacology in the context of migraine: utilization of a β-arrestin recruitment assayLisa McConnachie, Peter J Goadsby, Robert E Vann, et al.Pageof 3